Validation of the Hidradenitis Suppurativa Investigator Global Assessment
JAMA Dermatology · 2023
DOI: 10.1001/jamadermatol.2023.0797 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Dermatology, 2023. Verfasst von Amit Garg und 10 weiteren Autor:innen. Beteiligte Einrichtung: Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, New York. Hauptthemen laut MEDLINE: Hidradenitis Suppurativa. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Few simplified instruments exist for use in hidradenitis suppurativa (HS) trials.
Objective
To assess psychometric properties of the Hidradenitis Suppurativa Investigator Global Assessment (HS-IGA) score using a clinical trial data set. Design, Setting, and Participants This retrospective analysis of a phase 2 randomized double-blind, placebo-controlled, active-reference arm trial (UCB HS0001) included adults with moderate-to-severe HS. Exposures Trial participants were randomized at baseline to receive bimekizumab, adalimumab, or placebo. Main Outcomes and Measures The HS-IGA score at prespecified time points up to 12 weeks after randomization.
Results
The HS-IGA score showed strong convergent validity with IHS4 and HS-PhGA scores at baseline (Spearman correlation, 0.86 [ P < .001] and 0.74 [ P < .001], respectively) and at week 12 (Spearman correlation, 0.73 [ P < .001] and 0.64 [ P < .001], respectively). The HS-IGA scores assessed during predosing visits at screening and baseline showed good test-retest reliability (intraclass correlation coefficient [ICC] = 0.92). At week 12, HS-IGA responders were significantly associated with HiSCR-(50/75/90) responders (χ 2 = 18.45; P < .001; χ 2 = 18.11; P < .001; and χ 2 = 20.83; P < .001, respectively). The HS-IGA score was predictive of HiSCR-50/75/90 and HS-PhGA response at week 12 (AUC, 0.69, 0.73, 0.85, and 0.71, respectively). However, the HS-IGA as a measure of disease activity showed low predictive validity with patient-reported outcomes at week 12. Conclusions and Relevance The HS-IGA score demonstrated good psychometric properties compared with existing measures and may be considered for use as an end point in clinical trials for HS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, New York.
- Zema Consulting, Madison, Alabama.
- UCB Pharma, Colombes, France.
- UCB Pharma, Raleigh, North Carolina.
- UCB Pharma, Slough, United Kingdom.
- Department of Dermatology, Zealand University Hospital, Roskilde, Denmark.
Zitieren
APA
Garg, A., Zema, C., Ciaravino, V., Rolleri, R., Peterson, L., Garcia, L., Massaro, T., Jemec, G. B. E., Kirby, J. S., Thorlacius, L., & Ingram, J. R. (2023). Validation of the Hidradenitis Suppurativa Investigator Global Assessment. JAMA Dermatology. https://doi.org/10.1001/jamadermatol.2023.0797
Vancouver
Garg A, Zema C, Ciaravino V, Rolleri R, Peterson L, Garcia L, et al. Validation of the Hidradenitis Suppurativa Investigator Global Assessment. JAMA Dermatology. 2023. doi:10.1001/jamadermatol.2023.0797
BibTeX
@article{Garg2023,
author = {Garg, Amit and Zema, Carla and Ciaravino, Valerie and Rolleri, Robert and Peterson, Luke and Garcia, Llenalia and Massaro, Tyler and Jemec, Gregor B E and Kirby, Joslyn S and Thorlacius, Linnea and Ingram, John R},
title = {Validation of the Hidradenitis Suppurativa Investigator Global Assessment},
journal = {JAMA Dermatology},
year = {2023},
doi = {10.1001/jamadermatol.2023.0797}
}
EUVIMED